Binex buys 22% stake in Aprogen

Published: 2012-07-16 06:56:00

Updated: 2012-07-16 06:56:00

Binex Co. has bought a 22 percent stake in Aprogen from Schnell Biopharmaceuticals for 16 billion won to take lead in biosimilars, industry sources said Wednesday.

Biosimilars, or imitation biopharmaceuticals, are officially approved subsequent versions of innovative biopharmaceutical products...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK